拉莫三嗪片致重症多形性红斑1例分析

doi:10.19803/j.1672-8629.2020.11.19

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 835-837.
DOI: 10.19803/j.1672-8629.2020.11.19

拉莫三嗪片致重症多形性红斑1例分析

王晓¹, 吴玲娣¹, 王军², 魏伟³, 王维波^4,*, 王海英⁴

¹胜利油田中心医院,山东东营 257034;
²山东省食品药品审评认证中心,山东济南 250041;
³东营市食品药品检验中心,山东东营 257091;
⁴东营市人民医院,山东东营 257091

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
作者简介:王晓,女,硕士,主管药师,临床药学。

One Case of Lamotrigine-induced Severe Erythema Multiforme Drug Eruption

WANG Xiao¹, WU Lingdi¹, WANG Jun², WEI Wei³, WANG Weibo^4,*, WANG Haiying⁴

¹Sheng li Oilfield Central Hospital, Dongying Shandong 257034, China;
²Shandong Center for Food and Drug Evaluation & Certification, Jinan Shandong 250041, China;
³Inspection Center for Food and Drug, Dongying Shandong 257091, China;
⁴Dongying People's Hospital, Dongying Shandong 257091, China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的探讨拉莫三嗪致重症多形性红斑的处置措施。方法分析1例拉莫三嗪致重症多形性红斑的诊疗经过,结合文献检索,探讨拉莫三嗪致重症多形性红斑的机制和应对措施。结果患者服用拉莫三嗪第55天诊断为重症多形性红斑,立即停用并静脉滴注甲泼尼龙琥珀酸钠等相关治疗,患者病情逐步好转。停药第19天,患者皮疹明显好转,瘙痒感消失。结论拉莫三嗪致重症多形性红斑应立即停药,给予糖皮质激素等对症治疗。

关键词: 拉莫三嗪, 重症多形性红斑, 不良反应

Abstract: Objective To explore ways to treat Stevens Johnson syndrome induced by lamotrigine. Methods The diagnosis and treatment of one case of Stevens Johnson syndrome induced by lamotrigine was analyzed. The mechanism by which lamotrigine induced Stevens Johnson syndrome was discussed in combination with literature. Results The patient was diagnosed with Stevens Johnson syndrome on the 55th day he took lamotrigine. The drug was stopped immediately. His condition gradually improved after the treatment with intravenous methylprednisolone sodium succinate. Skin rash was significantly improved, and itching disappeared on the 19th day of withdrawal. Conclusion The use of lamotrigine should be stopped immediately should Stevens Johnson syndrome occur. Glucocorticoid and other drugs should be given as symptomatic treatment.

Key words: lamotrigine, Stevens Johnson syndrome, adverse reactions

中图分类号:

R994.11

王晓, 吴玲娣, 王军, 魏伟, 王维波, 王海英. 拉莫三嗪片致重症多形性红斑1例分析[J]. 中国药物警戒, 2020, 17(11): 835-837.

WANG Xiao, WU Lingdi, WANG Jun, WEI Wei, WANG Weibo, WANG Haiying. One Case of Lamotrigine-induced Severe Erythema Multiforme Drug Eruption[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 835-837.

参考文献

[1] Norio YF, Kojiro H, Koji T, et al. Comorbidity of Stevens Johnson syndrome and neutropenia associated with lamotrigine: a case report [J]. Gen Hosp Psychiatry, 2014, 36(6) : 761.e9-761.e11.
[2] CFDA. decides to revise the package insert of Lamotrigine Hydro-chloride Oral Solution[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2012, 14(3): 201.
[3] Stefani A, Spadoni F, Siniscalchi A, et al.Lamotrigine inhibits Ca²⁺currents in cortical neurons: functional implications[J].Eur J Pharmacol, 2006, 307(1): 113-116.
[4] Sarco DP, Bourgeois BF.The safety and tolerability of newer antiepileptic drugs in children and adolescents[J].CNS Drugs, 2010, 24(5): 399-430.
[5] Ng PP, Sun YJ, Tan HH, et al.Detection of herpes simplex virus genomic DNA in various subsets of erythema multiforme by polymerase chain reaction[J]. Dermatology, 2003, 207(4): 349-353.
[6] He X,Zhang Y,Xu J, et al.Literature analysis of 77 cases of adverse reactions of lamotrigine[J]. China Pharmacovigilance(药物不良反应杂志), 2016,13(5): 303-305.
[7] Li DK, Jin YY, Tang G, et al.Martindale's Drug Dictionary[S]. 35th ed. 2009, 383-385.
[8] Codrea P, Tigaran S, Sidenius P, et al.Lamotrigine-induced rash-worth a rechallenge[J]. Acta Neurol Scand, 2005, 111(3): 191-194.
[9] Cheng XM, Li L, Tian YJ.Progress in the study of HLA-B1502 allele and severe cutaneous adverse reactions caused by antiep-ileptic drugs in different ethnic groups[J]. China Pharmacovigilance(药物不良反应杂志). 2011, 8(4) : 237-239.
[10] Myers AP, Watson TA, Strock SB.Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by lamotrigine ginseng drug interaction[J]. Pharmacotherapy, 2015, 35(3): e9-12.
[11] Ginory A, Charncy-Catchpole M.Drug reaction with eosinophilia and systemic symptoms(dress)in an adolescent treated with lamotrigine[J]. J Pediatr Pharmacol Ther, 2013, 18(3): 236-240.
[12] Hirata I, Kimizu T, Ikeda T, et al.A fatal case of lamotrigine associated drug-induced hypersensitivity syndrome with fulminant myocarditis[J]. No To Hatatsu, 2013, 45(3): 243-244.
[13] Shi YW, Min F L, Zhou D, et al.HLA-A*2402 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions[J]. Neurology, 2017, 88(23): 2183-2191.
[14] Teh LK, Selvaraj M, Bannur Z, et al.Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*1502[J]. J Pharm Pharm Sci, 2016, 19(1): 147-160.
[15] Deng Y, Li S, Zhang L, et al.Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis[J]. Seizure, 2018, 60: 163-171.
[16] Burkhart KK, Abernethy D, Jackson D.Data mining faers to analyze molecular targets of drugs highly associated with Stevens-Johnson syndrome[J]. J Med Toxicol, 2015, 11(2): 265-273.

拉莫三嗪片致重症多形性红斑1例分析

One Case of Lamotrigine-induced Severe Erythema Multiforme Drug Eruption

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.